Skip to main content

Table 4 Quantitative measures of left ventricular function

From: Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial

Variable

Placebo (95 % CI)

WJMSCs(95 % CI)

P value

(number = 55)

(number = 57)

Global LVEF (%)

   

Baseline

   

 Mean

51.0±1.1(48.8~53.3)

52.1±1.0(50.2~54.1)

0.46

4 Months

   

 Mean

54.2±0.9(52.5~56.1)

58.5±0.7(57.1~60.0)

0.0003

 Difference

3.2±0.9(1.4~5.0)

6.4±0.7(4.9~7.9)

0.008

 P value (baseline vs.6 months)

0.0009

<0.0001

 

12 Months

   

 Mean

54.5±0.8(52.8~56.2)

58.8±0.8(57.3~60.4)

0.0002

 Difference

3.5±0.8(1.9~5.0)

6.7±0.8(5.1~8.3)

0.004

 P value (baseline vs.12 months)

<0.0001

<0.0001

 

18 Months

   

 Mean

54.0±0.8( 52.3~55.7)

60.0±0.5 (58.9~61.0)

<0.0001

 Difference

2.8±1.2(0.4~5.1)

7.8±0.9(6.0~9.7)

0.001

 P value (baseline vs.18 months)

0.05

<0.0001

 

LVFS (%)

   

Baseline

   

 Mean

26.6±0.7(25.2~27.9)

27.3±0.6(26.0~28.6)

0.42

4 Months

   

 Mean

29.7±0.7(28.3~31.0)

32.6±0.6(31.4~33.9)

0.002

 Difference

3.1±0.6(1.9~4.3)

5.3±0.6(4.0~6.6)

0.01

 P value (baseline vs.6 months)

<0.0001

<0.0001

 

12 Months

   

 Mean

29.8±0.6(28.5~31.0)

32.7±0.5(31.7~33.8)

0.0005

 Difference

3.2±0.5(2.1~4.3)

5.4±0.5(4.3~6.5)

0.005

 P value (baseline vs.12 months)

<0.0001

<0.0001

 

18 Months

   

 Mean

28.6±0.6(20.8~35.6)

33.6±0.5(27.3~39.1)

<0.0001

 Difference

2.1±0.8(−8.9~13.5)

6.2±0.7(−4.1~16.4)

<0.0001

 P value (baseline vs.18 months)

0.01

<0.0001

 

WMSI (17-segment model)

   

Baseline

   

 Mean

1.28±0.03(1.23~1.34)

1.29±0.03(1.24~1.34)

0.76

4 Months

   

 Mean

1.16±0.02(1.11~1.21)

1.10±0.01(1.07~1.12)

0.02

 Difference

−0.12±0.02(−0.16~−0.09)

−0.19±0.02(−0.23~−0.16)

0.003

 P value (baseline vs.6 months)

<0.0001

<0.0001

 

12 Months

   

 Mean

1.15±0.02(1.11~1.20)

1.09±0.02(1.06~1.12)

0.02

 Difference

−0.13±0.02( −0.17~−0.10)

−0.20±0.02(−0.23~−0.17)

0.003

 P value (baseline vs.12 months)

<0.0001

<0.0001

 

18 Months

   

 Mean

1.16±0.9(1.02~1.40)

1.07±0.01(1.00~1.17)

<0.0001

 Difference

−0.13±0.02(−0.42~0.08)

−0.22±0.02(−0.57~0.04)

0.01

 P value (baseline vs.18 months)

<0.0001

<0.0001

 

End-systolic volume (ml)

   

Baseline

   

 Mean

66.0±3.1(59.8~72.2)

63.1±2.8(57.5~68.7)

0.38

4 Months

   

 Mean

63.4±2.8(57.7~69.0)

55.9±2.1(51.7~60.2)

0.07

 Difference

−2.6±1.8(−6.4~1.1)

−7.2±1.9(−10.9~−3.5)

0.09

 P value (baseline vs.6 months)

0.16

0.0003

 

12 Months

   

 Mean

62.5±2.8(56.9~68.0)

55.1±2.1(50.9~59.4)

0.06

 Difference

−3.5±1.9(−7.3~0.2)

−8.0±2.0(−12.1~−3.9)

0.12

 P value (baseline vs.12 months)

0.11

0.0002

 

18 Months

   

 Mean

62.8±0.9(59.1~66.6)

49.2±1.0(47.1~51.2)

<0.0001

 Difference

−2. 9±2.1(−7.1~1.3)

−14.0±2.2(−18.4~−9.5)

0.0004

 P value (baseline vs.18 months)

0.2

<0.0001

 

End-diastolic volume (ml)

   

Baseline

   

 Mean

132.2±3.9(124.3~140.0)

130.3±3.8(122.7~137.9)

0.49

4 Months

   

 Mean

136.0±4.0(127.9~144.0)

133.2±3.2(126.8~139.5)

0.72

 Difference

3.8±2.3(−0.7~8.4)

2.9±2.6(−2.3~8.0)

0.78

 P value (baseline vs.6 months)

0.20

0.07

 

12 Months

   

 Mean

134.5±3.9(126.6~142.4)

131.9±3.1(125.8~138.1)

0.60

 Difference

2.4±2.5(−2.6~7.3)

1.6±2.8(−4.0~7.2)

0.84

 P value (baseline vs.12 months)

0.45

0.22

 

18 Months

   

 Mean

136.4±3.1(130.1~142.7)

122.7±1.6 (119.5~125.8)

0.0001

 Difference

4.1±2.4(−0.8~9.0)

−7.6±3.13(−13.9~−1.4)

0.004

 P value (baseline vs.18 months)

0.1

<0.0001

 
  1. LVEF, LVESV and LVEDV by two dimensional-ECG from baseline to 18 months post-treatment between the WJMSC group and placebo-control group were analyzed by ANCOVA. Treatment effects are expressed as differences in least-squares means (ANCOVA model) with 95 % CI ANCOVA analysis of covariance, CI confidence interval, ECG echocardiogram, LVEDV left ventricular end-diastolic volume, LVESF left ventricular end-systolic volume, WJMSC Wharton’s jelly-derived mesenchymal stem cells